Recent Updates
Recently added Catalysts
LYRA

Lyra Therapeutics to Participate in Upcoming Investor Conferences

Key Takeaway: WATERTOWN, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President an

Full Press Release Details

WATERTOWN, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences in September:
H.C. Wainwright 25th Annual Global Investment Conference – Fireside chat on Wednesday, September 13th at 2:00 p.m. ET
Cantor Global Healthcare Conference 2023 – Fireside chat on Tuesday, September 26th at 4:20 p.m. ET
Live webcast of the presentations will be available on the Investor Relations section of the Company's website at investors.lyratherapeutics.com. Replays of the webcasts will be available for 30 days following the presentation.
About Lyra Therapeutics

Contact Data

Contact Information:
Ellen Cavaleri, Investor Relations

Contact

With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!
Already have an account? Log in here.
Last updated: Sep 6, 2023